Sorrel Wolowacz, Lynda Doward Ask "Can We Do Better?" Measuring Utility Values in Clinical Trials

Share on: 
Lynda Doward (L) and Sorrel Wolowacz (R)

Together with colleagues from the University of Glasgow and Biogen Idec, Sorrel Wolowacz, Head of European Health Economics, and Lynda Doward, European Head of Patient-Reported Outcomes, co-authored an article in ISPOR Connections. They explore common issues related to the measurement of health state utility values for economic models in clinical trials and introduce the work of the ISPOR Task Force that is developing best practice guidelines on this topic. 

Read the article here on ISPOR's website

Related Services:
Staff Members: